



July 5, 2011
Toyobo Co., Ltd.

Toyobo to Increase Capacity for Injections in Its Contract Manufacturing of Pharmaceutical Business

Toyobo has decided to increase its production capacity for injections in its contract manufacturing of pharmaceutical business.

1. Background

Along with the increase in adult-onset diseases around the world, the pharmaceutical industry has developed many types of new drugs, focusing around low-molecular weight compounds.

However, because of the increasing difficulty of developing new pharmaceuticals and the expiration of the patents on major drugs around 2010, pharmaceutical companies are concentrating on developing effective biopharmaceuticals for use in the treatment of cancer and autoimmune diseases. Looking to the future, the world drug market is forecast to show continued expansion of about 20% annually.

Toyobo has thus far accumulated a wealth of experience in the development and production of biopharmaceuticals and has expanded its contract pharmaceutical production business to include items ranging from early-stage diagnostic preparations to drugs for treatment.

In view of these various industry trends, Toyobo has made the decision to add another production line for injections to meet expanding demand in the biopharmaceutical market.

2. Outline of the Capacity Increase

Location: Pharmaceutical Plant (Otsu, Shiga Prefecture)

Production capacity: Injection capacity for 1,800 vials/hour of injectable aseptic fillings and a related freeze drying machine

Investment: Approximately ¥1.2 billion

Start-up date: January 2013 (Scheduled to reach full operation during fiscal 2013)

For more information, contact:

The Toyobo Public Relations Group

pr_g@toyobo.jp